29274-22-4

Basic information

• Product Name: 5-Hydroxypyrazolo[1,5-a]pyrimidine
• Synonyms: 5-Hydroxypyrazolo[1,5-a]pyrimidine;Pyrazolo[1,5-a]pyrimidin-5-ol;4H,5H-pyrazolo[1,5-a]pyriMidin-5-one;1H-pyrazolo[1,5-a]pyrimidin-5-one;pyrazolo[1,5-a]pyrimidin-5(4H)-one(WXC06578)
• CAS NO: 29274-22-4
• Molecular Formula: C₆H₅N₃O
• Molecular Weight: 135.126
• Mol File: 29274-22-4.mol
• Article Data: 25

Chemical Properties

• Boiling Point: 243.174°C at 760 mmHg
• Flash Point: 100.868°C
• Appearance: /
• Density: 1.511g/cm³
• Vapor Pressure: 0.033mmHg at 25°C
• Refractive Index: 1.739
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 5-Hydroxypyrazolo[1,5-a]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Hydroxypyrazolo[1,5-a]pyrimidine(29274-22-4)
• EPA Substance Registry System: 5-Hydroxypyrazolo[1,5-a]pyrimidine(29274-22-4)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 29274-22-4(Hazardous Substances Data)

Usage

General Description

5-Hydroxypyrazolo[1,5-a]pyrimidine is a chemical compound with the molecular formula C4H4N4O. It is a heterocyclic compound containing a pyrazolopyrimidine core structure. 5-Hydroxypyrazolo[1,5-a]pyrimidine has been identified as an inhibitor of the enzyme cyclic GMP-specific phosphodiesterase type 5 (PDE5), which is involved in the regulation of blood flow in the body. Inhibiting PDE5 can lead to vasodilation and increased blood flow, making it useful in the treatment of erectile dysfunction. Due to its pharmaceutical potential, 5-Hydroxypyrazolo[1,5-a]pyrimidine has been studied for its therapeutic applications and is a key component in the development of erectile dysfunction medications like Viagra.

InChI:InChI=1/C6H5N3O/c10-6-2-4-9-5(8-6)1-3-7-9/h1-4H,(H,8,10)

Upstream product

• 874-14-6 1,3-dimethyluracil 
• 1225387-53-0 3⁽⁵⁾-aminopyrazole 
• 1001-26-9 ethyl 3-ethoxyacrylate 
• 1820-80-0 3-aminopyrazole 
• 105-37-3 Ethyl propionate 
• 5941-55-9 ethyl 3-ethoxyacrylate 
• 623-47-2 propynoic acid ethyl ester 
• 89464-32-4 prop-2-ynylcarbamic acid ethyl ester 
• 1224944-43-7 sodium pyrazolo[1,5-a] pyrimidin-5-olate 
• 922-67-8 propynoic acid methyl ester 

Downstream Products

• 29274-25-7 4-methylpyrazolo[1,5-a]pyrimidin-5(4H)-one 
• 29274-24-6 5-chloropyrazolo[1,5-a]pyrimidine 
• 1086375-50-9 pyrazolo [1,5-a]pyrimidine-5-carboxylic acid 
• 72851-88-8 5-phenyl-pyrazolo[1,5-a]pyrimidine 
• 1228352-12-2 5-(phenylethynyl)pyrazolo[1,5-a]pyrimidine 

Relevant articles and documents

Design, synthesis and biological evaluation of macrocyclic derivatives as TRK inhibitors

Tropomyosin receptor kinases (TRKA, TRKB, TRKC) are transmembrane receptor tyrosine kinases, which are respectively encoded by NTRK1, NTRK2, and NTRK3 genes. Herein, we reported the design, synthesis and Structure-Activity Relationship (SAR) investigation of a series of macrocyclic derivatives as new TRK inhibitors. Among these compounds, compound 9e exhibited strong kinase inhibitory activity (TRKG595R IC50 = 13.1 nM) and significant antiproliferative activity in the Ba/F3-LMNA-NTRK1 cell line (IC50 = 0.080 μM) and compound 9e has shown a better inhibitory effect (IC50 = 0.646 μM) than control drug LOXO-101 in Ba/F3-LMNA-NTRK1-G595R cell line. These results indicate that compound 9e is a potential TRK inhibitor for further investigation.

Preparation and application of protein receptor kinase inhibitor

The invention provides a preparation method of a protein receptor kinase inhibitor. Specifically, the invention discloses a compound as shown in a formula I or a stereoisomer or racemate or pharmaceutically acceptable salt thereof, and the definition of each group is as shown in the specification. The invention also discloses application of the compound as a TRK kinase inhibitor.

Heterocyclic Compound

The present invention provide a compound having an orexin receptor antagonistic activity, which is expected to be useful as medicaments such as agents for the prophylaxis or treatment of sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.